Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_assertion type Assertion NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_head.
- NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_assertion description "[Crizotinib was the first clinically relevant ALK inhibitor, now approved for the treatment of late-stage and metastatic cases of lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_provenance.
- NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_assertion evidence source_evidence_literature NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_provenance.
- NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_assertion SIO_000772 25421750 NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_provenance.
- NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_assertion wasDerivedFrom befree-2016 NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_provenance.
- NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_assertion wasGeneratedBy ECO_0000203 NP1239691.RA-JZoOqGwwSjRTTnhzurvm38on0HSW9HJr8IrPvfqbv8130_provenance.